The Long Journey towards Personalized Targeted Therapy in Poorly Differentiated Thyroid Carcinoma (PDTC): A Case Report and Systematic Review
Journal of Personalized Medicine · 18.06.2024 · 14 (6) · 654
DOI: 10.3390/jpm14060654 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Personalized Medicine, online erschienen am 18.06.2024. Verfasst von Odysseas Violetis und 11 weiteren Autor:innen. Beteiligte Einrichtung: 2nd Department of Surgery, Aretaieio Athens Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Poorly differentiated thyroid carcinoma (PDTC) has an intermediate prognosis between indolent well-differentiated thyroid carcinoma (TC) and anaplastic carcinoma. Herein, we present a case report with a PDTC component, along with a systematic review of the literature. Case Report: We report a case of a 45-year-old man diagnosed with a PDTC component, along with hobnail and tall-cell variant features positive for BRAFV600E mutation, after a total thyroidectomy and neck dissection. Radioactive iodine (RAI)-131 therapy was applied, but an early recurrence led to complementary surgeries. The anti-Tg rise, the presence of new lymph nodes, and the negative whole-bodyradioiodine scan were suggestive of a radioiodine-resistant tumor. Lenvatinib, sorafenib, dabrafenib/trametinib, cabozantinib and radiotherapy were all administered, controlling the tumor for a period of time before the patient ultimately died post-COVID infection. Systematic Review: We searched PubMed, Scopus, and WebofScience to identify studies reporting clinicopathological characteristics, molecular marker expression, and management of non-anaplastic TC with any proportion of PDTC in adult patients. Of the 2007 records retrieved, 82were included in our review (PROSPERO-ID545847).
Conclusions
Our case, together with the systematic review, imply that a combination of molecular-targetedtreatments may be safe and effective in patients with RAI-resistantBRAF-mutated advanced PDTC when surgery has failed to control tumor progression.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- 2nd Department of Surgery, Aretaieio Athens Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
- Endocrine Surgery Department, Athens Medical Center, 15125 Athens, Greece.
- Department of Pathology, Medical School, University of Athens, 11527 Athens, Greece.
- European Neuroendocrine Tumor Society (ENETS) Center of Excellence, Ekpa-Laiko Center, 11527 Athens, Greece.
- IATROPOLIS Private Medical Center, 11521 Athens, Greece.
- Department of Oncology, Ippokrateio Athens General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
ORCID-Profile: Ariadni Spyroglou, Antonios Xydakis, George Mastorakos, Krystallenia I Alexandraki
Zitieren
APA
Violetis, O., Konstantakou, P., Spyroglou, A., Xydakis, A., Kekis, P. B., Tseleni, S., Kolomodi, D., Konstadoulakis, M., Mastorakos, G., Theochari, M., Aller, J., & Alexandraki, K. I. (2024). The Long Journey towards Personalized Targeted Therapy in Poorly Differentiated Thyroid Carcinoma (PDTC): A Case Report and Systematic Review. Journal of Personalized Medicine, 14(6), 654. https://doi.org/10.3390/jpm14060654
Vancouver
Violetis O, Konstantakou P, Spyroglou A, Xydakis A, Kekis PB, Tseleni S, et al. The Long Journey towards Personalized Targeted Therapy in Poorly Differentiated Thyroid Carcinoma (PDTC): A Case Report and Systematic Review. Journal of Personalized Medicine. 2024;14(6):654. doi:10.3390/jpm14060654
BibTeX
@article{Violetis2024,
author = {Violetis, Odysseas and Konstantakou, Panagiota and Spyroglou, Ariadni and Xydakis, Antonios and Kekis, Panagiotis B and Tseleni, Sofia and Kolomodi, Denise and Konstadoulakis, Manousos and Mastorakos, George and Theochari, Maria and Aller, Javier and Alexandraki, Krystallenia I},
title = {The Long Journey towards Personalized Targeted Therapy in Poorly Differentiated Thyroid Carcinoma (PDTC): A Case Report and Systematic Review},
journal = {Journal of Personalized Medicine},
year = {2024},
volume = {14},
number = {6},
pages = {654},
doi = {10.3390/jpm14060654}
}
EUVIMED